Is there any relationship between gene expression of tumor antigens and CD4(+) T cells in multiple myeloma?

Página do item simplificado
dc.contributor.authorBraga, Walter M. T.
dc.contributor.authorSilva, Bruna R. da [UNIFESP]
dc.contributor.authorAlves, Veruska L. F. [UNIFESP]
dc.contributor.authorBortoluzo, Adriana B.
dc.contributor.authorAtanackovic, Djordje
dc.contributor.authorColleoni, Gisele W. B. [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionInsper Inst Educ & Res
dc.contributor.institutionUniv Med Ctr Hamburg Eppendorf
dc.date.accessioned2016-01-24T14:37:17Z
dc.date.available2016-01-24T14:37:17Z
dc.date.issued2014-05-01
dc.description.abstractAim: the present study aimed at correlating the expression of cancer/testis antigens (CTAs) with the expression of genes related to tumor-infiltrating T cells. Materials & methods: MAGE-C1/CT-7, MAGEA3/6, NY-ESO-1, LAGE-1 and GAGE expression were evaluated in 46 bone marrow multiple myeloma (MM) aspirates by RT-PCR. Expression of FOXP3/CTLA4 and RORyt, as markers for Tregs and Th17 cells, respectively, was investigated by quantitative PCR. Results: MAGEC1/CT7 was expressed in 66% of MM samples. We did not find correlation between the presence of single CTA and expression of CTLA4 or RORyt neither expression of CD4(+) T-cell markers and the number of CTA simultaneously expressed in the tumor. However, we did observe a correlation between the percentage of plasma cells and the number of CTAs expressed in the patients' bone marrow. Conclusion: Although CTAs and immunomodulatory CD4(+) T cells represent potential targets for immunotherapy in MM, we did not find association among expression of such genes in MM.en
dc.description.affiliationUniversidade Federal de São Paulo, Disciplina Hematol & Hemoterapia, Dept Oncol Clin & Expt, São Paulo, Brazil
dc.description.affiliationInsper Inst Educ & Res, São Paulo, Brazil
dc.description.affiliationUniv Med Ctr Hamburg Eppendorf, Hamburg, Germany
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Disciplina Hematol & Hemoterapia, Dept Oncol Clin & Expt, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIDFAPESP: 2010/17668-6
dc.format.extent569-575
dc.identifierhttp://dx.doi.org/10.2217/IMT.14.24
dc.identifier.citationImmunotherapy. London: Future Medicine Ltd, v. 6, n. 5, p. 569-575, 2014.
dc.identifier.doi10.2217/IMT.14.24
dc.identifier.issn1750-743X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/37757
dc.identifier.wosWOS:000337220000012
dc.language.isoeng
dc.publisherFuture Medicine Ltd
dc.relation.ispartofImmunotherapy
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectcancer/testis antigenen
dc.subjectmultiple myelomaen
dc.subjectTh17en
dc.subjectTregen
dc.titleIs there any relationship between gene expression of tumor antigens and CD4(+) T cells in multiple myeloma?en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos